Literature DB >> 25346426

Contribution of MDR1 gene polymorphisms on IBD predisposition and response to glucocorticoids in IBD in a Chinese population.

Qing Fan Yang1, Bai Li Chen, Qing Sen Zhang, Zhen Hua Zhu, Bin Hu, Yao He, Xiang Gao, Yi Ming Wang, Pin Jin Hu, Min Hu Chen, Zhi Rong Zeng.   

Abstract

OBJECTIVE: The cornerstone of conventional treatment for inflammatory bowel disease (IBD) is glucocorticoid (GC). Single nucleotide polymorphisms (SNPs) of genes such as multidrug resistance 1 (MDR1) are related to patient's response to GC, and MDR1 polymorphisms are associated with susceptibility to IBD in Caucasians. We aimed to investigate whether the polymorphisms of five genes including MDR1 influence the response to GC in Chinese patients and the relationship between MDR1 and IBD susceptibility.
METHODS: SNPs were selected and genotyped in 156 IBD patients treated with GC and 223 healthy controls. Patients were evaluated and classified as GC-dependent, GC-resistant or responsive to GC after treatment.
RESULTS: The CC genotypes of rs1128503 and rs1045642 in MDR1 gene were more frequent in Crohn's disease (CD) patients who were GC-dependent than in those responsive to GC (odds ratio [OR] 6.583, 95% confidence interval [CI] 1.760-24.628, P = 0.019 and OR 3.873, 95% CI 1.578-9.506, P = 0.009, respectively). The G allele of MDR1 rs2032582 was less frequent among CD patients than in controls (OR 0.668, 95% CI 0.484-0.921, P = 0.014). G allele carriers were also less likely to develop non-stricturing and non-penetrating CD (OR 0.661, 95% CI 0.462-0.946, P = 0.023) and ileocolonic CD (OR 0.669, 95% CI 0.472-0.948, P = 0.024).
CONCLUSIONS: Polymorphisms of MDR1 are associated with patient's GC response and a predisposition to CD in Chinese population. Further studies are needed to elucidate the role of MDR1 polymorphisms in IBD and that as genetic markers for GC response.
© 2014 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  drug resistance; glucocorticoids; inflammatory bowel diseases; phenotype; single nucleotide polymorphism

Mesh:

Substances:

Year:  2015        PMID: 25346426     DOI: 10.1111/1751-2980.12205

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  15 in total

1.  P-glycoprotein gene MDR1 polymorphisms and susceptibility to systemic lupus erythematosus in Guangxi population: a case-control study.

Authors:  Jian Wang; Yanqiong Liu; Jiangyang Zhao; Juanjuan Xu; Shan Li; Xue Qin
Journal:  Rheumatol Int       Date:  2017-02-02       Impact factor: 2.631

2.  Amelioration of experimental colitis after short-term therapy with glucocorticoid and its relationship to the induction of different regulatory markers.

Authors:  Helioswilton Sales-Campos; Patrícia R de Souza; Paulo J Basso; Viviani Nardini; Angelica Silva; Fernanda Banquieri; Vanessa B F Alves; Javier E L Chica; Auro Nomizo; Cristina R B Cardoso
Journal:  Immunology       Date:  2016-10-07       Impact factor: 7.397

Review 3.  CTLA-4 and MDR1 polymorphisms increase the risk for ulcerative colitis: A meta-analysis.

Authors:  Jia-Jun Zhao; Di Wang; Hui Yao; Da-Wei Sun; Hong-Yu Li
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

Review 4.  The ATP-binding cassette proteins ABCB1 and ABCC1 as modulators of glucocorticoid action.

Authors:  Kerri Devine; Elisa Villalobos; Catriona J Kyle; Ruth Andrew; Rebecca M Reynolds; Roland H Stimson; Mark Nixon; Brian R Walker
Journal:  Nat Rev Endocrinol       Date:  2022-10-11       Impact factor: 47.564

5.  Intrarectally administered polaprezinc attenuates the development of dextran sodium sulfate-induced ulcerative colitis in mice.

Authors:  Zhaoyang Liu; Wenbo Xie; Mingru Li; Jing Liu; Xiao Liang; Tao Li
Journal:  Exp Ther Med       Date:  2019-10-31       Impact factor: 2.447

6.  Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms.

Authors:  Andrew Leber; Raquel Hontecillas; Victoria Zoccoli-Rodriguez; Josep Bassaganya-Riera
Journal:  Inflamm Bowel Dis       Date:  2018-08-16       Impact factor: 5.325

Review 7.  Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology.

Authors:  Karen Dubois-Camacho; Payton A Ottum; Daniel Franco-Muñoz; Marjorie De la Fuente; Alejandro Torres-Riquelme; David Díaz-Jiménez; Mauricio Olivares-Morales; Gonzalo Astudillo; Rodrigo Quera; Marcela A Hermoso
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

8.  Polymorphisms in the multidrug-resistance 1 gene related to glucocorticoid response in rheumatoid arthritis treatment.

Authors:  Bart V J Cuppen; Katerina Pardali; Maarten C Kraan; Anne C A Marijnissen; Linda Yrlid; Marita Olsson; Johannes W J Bijlsma; Floris P J G Lafeber; Ruth D E Fritsch-Stork
Journal:  Rheumatol Int       Date:  2017-01-28       Impact factor: 2.631

9.  Unique β-Glucuronidase Locus in Gut Microbiomes of Crohn's Disease Patients and Unaffected First-Degree Relatives.

Authors:  Karine Gloux; Jamila Anba-Mondoloni
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

10.  Genetic Polymorphisms of Multidrug Resistance Gene-1 (MDR1/ABCB1) and Glutathione S-Transferase Gene and the Risk of Inflammatory Bowel Disease among Moroccan Patients.

Authors:  Nezha Senhaji; Yaya Kassogue; Mina Fahimi; Nadia Serbati; Wafaa Badre; Sellama Nadifi
Journal:  Mediators Inflamm       Date:  2015-10-28       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.